Prevalence and clinicopathologic correlates of o6-methylguanine- dna methyltransferase methylation status in patients with triple-negative breast cancer treated preoperatively by alkylating drugs

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background Predictive factors of benefit from specific chemotherapy regimens are not currently available in triple-negative breast cancer (TNBC). MGMT (O6-methylguanine-DNA methyltransferase) controls DNA repair pathways, and its epigenetic silencing is used for predicting the response to the alkylating drug temozolomide in patients with glioma. Materials and Methods The study population was composed of 84 patients with TNBC treated with alkylating agents and evaluated for clinicopathologic parameters (tumor shrinkage and pathologic complete response [pCR]). MGMT methylation status was assessed in formalin-fixed, paraffin-embedded tumor specimens by pyrosequencing. The samples were categorized as methylated (mean methylation value > 5%), indeterminate (4%-5%), and unmethylated (≤3%). Results MGMT methylation status was successfully evaluated in all the cases: 58.3% were methylated; 27.4%, unmethylated; and 14.3%, indeterminate. MGMT methylation was observed in 80%, 62%, and 29% of patients showing a 100%, 99% to 30%, and

Original languageEnglish
Pages (from-to)285-290
Number of pages6
JournalClinical Breast Cancer
Volume14
Issue number4
DOIs
Publication statusPublished - 2014

Fingerprint

Triple Negative Breast Neoplasms
Methyltransferases
Methylation
DNA Methylation
temozolomide
Pharmaceutical Preparations
Alkylating Agents
Epigenomics
Glioma
DNA Repair
Paraffin
Formaldehyde
Neoplasms
Drug Therapy
O-(6)-methylguanine
DNA
Population

Keywords

  • DNA repair
  • Epigenetic alterations
  • Mammary tumors
  • Neoadjuvant therapy
  • Prognosis

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

@article{cf717cb403054f8ba24f46d0943f89a0,
title = "Prevalence and clinicopathologic correlates of o6-methylguanine- dna methyltransferase methylation status in patients with triple-negative breast cancer treated preoperatively by alkylating drugs",
abstract = "Background Predictive factors of benefit from specific chemotherapy regimens are not currently available in triple-negative breast cancer (TNBC). MGMT (O6-methylguanine-DNA methyltransferase) controls DNA repair pathways, and its epigenetic silencing is used for predicting the response to the alkylating drug temozolomide in patients with glioma. Materials and Methods The study population was composed of 84 patients with TNBC treated with alkylating agents and evaluated for clinicopathologic parameters (tumor shrinkage and pathologic complete response [pCR]). MGMT methylation status was assessed in formalin-fixed, paraffin-embedded tumor specimens by pyrosequencing. The samples were categorized as methylated (mean methylation value > 5{\%}), indeterminate (4{\%}-5{\%}), and unmethylated (≤3{\%}). Results MGMT methylation status was successfully evaluated in all the cases: 58.3{\%} were methylated; 27.4{\%}, unmethylated; and 14.3{\%}, indeterminate. MGMT methylation was observed in 80{\%}, 62{\%}, and 29{\%} of patients showing a 100{\%}, 99{\%} to 30{\%}, and",
keywords = "DNA repair, Epigenetic alterations, Mammary tumors, Neoadjuvant therapy, Prognosis",
author = "Caterina Fumagalli and {Della Pasqua}, Silvia and Vincenzo Bagnardi and Anna Cardillo and Andrea Sporchia and Marco Colleoni and Giuseppe Viale and Massimo Barberis and Giancarlo Pruneri",
year = "2014",
doi = "10.1016/j.clbc.2014.02.010",
language = "English",
volume = "14",
pages = "285--290",
journal = "Clinical Breast Cancer",
issn = "1526-8209",
publisher = "Elsevier",
number = "4",

}

TY - JOUR

T1 - Prevalence and clinicopathologic correlates of o6-methylguanine- dna methyltransferase methylation status in patients with triple-negative breast cancer treated preoperatively by alkylating drugs

AU - Fumagalli, Caterina

AU - Della Pasqua, Silvia

AU - Bagnardi, Vincenzo

AU - Cardillo, Anna

AU - Sporchia, Andrea

AU - Colleoni, Marco

AU - Viale, Giuseppe

AU - Barberis, Massimo

AU - Pruneri, Giancarlo

PY - 2014

Y1 - 2014

N2 - Background Predictive factors of benefit from specific chemotherapy regimens are not currently available in triple-negative breast cancer (TNBC). MGMT (O6-methylguanine-DNA methyltransferase) controls DNA repair pathways, and its epigenetic silencing is used for predicting the response to the alkylating drug temozolomide in patients with glioma. Materials and Methods The study population was composed of 84 patients with TNBC treated with alkylating agents and evaluated for clinicopathologic parameters (tumor shrinkage and pathologic complete response [pCR]). MGMT methylation status was assessed in formalin-fixed, paraffin-embedded tumor specimens by pyrosequencing. The samples were categorized as methylated (mean methylation value > 5%), indeterminate (4%-5%), and unmethylated (≤3%). Results MGMT methylation status was successfully evaluated in all the cases: 58.3% were methylated; 27.4%, unmethylated; and 14.3%, indeterminate. MGMT methylation was observed in 80%, 62%, and 29% of patients showing a 100%, 99% to 30%, and

AB - Background Predictive factors of benefit from specific chemotherapy regimens are not currently available in triple-negative breast cancer (TNBC). MGMT (O6-methylguanine-DNA methyltransferase) controls DNA repair pathways, and its epigenetic silencing is used for predicting the response to the alkylating drug temozolomide in patients with glioma. Materials and Methods The study population was composed of 84 patients with TNBC treated with alkylating agents and evaluated for clinicopathologic parameters (tumor shrinkage and pathologic complete response [pCR]). MGMT methylation status was assessed in formalin-fixed, paraffin-embedded tumor specimens by pyrosequencing. The samples were categorized as methylated (mean methylation value > 5%), indeterminate (4%-5%), and unmethylated (≤3%). Results MGMT methylation status was successfully evaluated in all the cases: 58.3% were methylated; 27.4%, unmethylated; and 14.3%, indeterminate. MGMT methylation was observed in 80%, 62%, and 29% of patients showing a 100%, 99% to 30%, and

KW - DNA repair

KW - Epigenetic alterations

KW - Mammary tumors

KW - Neoadjuvant therapy

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=84904676264&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904676264&partnerID=8YFLogxK

U2 - 10.1016/j.clbc.2014.02.010

DO - 10.1016/j.clbc.2014.02.010

M3 - Article

C2 - 24709436

AN - SCOPUS:84904676264

VL - 14

SP - 285

EP - 290

JO - Clinical Breast Cancer

JF - Clinical Breast Cancer

SN - 1526-8209

IS - 4

ER -